^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TFF1 overexpression + ER positive

    i
    Other names: TFF1, Trefoil Factor 1, HP1.A, PNR-2, PS2, Breast Cancer Estrogen-Inducible Protein, Polypeptide P1.A, Protein PS2, D21S21, BCEI, HPS2, Breast Cancer Estrogen-Inducible Sequence Expressed In, Breast Cancer Estrogen-Inducible Sequence, Gastrointestinal Trefoil Protein PS2, ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099; 7031
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    almost2years
    TFF1 and TFF3 predict response to CDK4/6 inhibitors in breast cancer patients (AACR 2023)
    Correlation analysis showed a strong negative correlation between TFF1 and TFF3 levels to IC50 values of palbociclib and abemaciclib. Our results identified and validated the common biomarkers, TFF1 and TFF3, as predictors of CDK4/6i response efficacy in ER-positive, HER2-negative BC patients. These findings provide a predictive tool capable of selecting de novo metastatic BC patients who will have the greatest benefit from the combination of CDK4/6i with endocrine treatment. Furthermore, our discovery of biomarkers in early versus late progression on CDK4/6i therapy will enable new therapeutic avenues and provide the rationale for future large-scale clinical trials.
    Clinical • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • CCR4 (C-C Motif Chemokine Receptor 4) • CCR7 (Chemokine (C-C motif) receptor 7) • TFF1 (Trefoil Factor 1) • TFF3 (Trefoil factor 3)
    |
    ER positive • HER-2 negative • TFF1 overexpression + ER positive • TFF3 overexpression + ER positive • TFF3 expression
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib)